August 5, 2009 — The US Food and Drug Administration (FDA) has approved a long-acting, once-monthly formulation of paliperidone palmitate injection (Invega Sustenna, Janssen, a division of ...

Results served as basis for regulatory filing with U.S. Food and Drug Administration and designation as Priority Review TITUSVILLE, N.J., March 29, 2015 /PRNewswire/ -- Three-month paliperidone ...

Janssen announced today that the Scottish Medicines Consortium (SMC) has accepted paliperidone palmitate (Trevicta ®) for use within NHS Scotland. Paliperidone palmitate (Trevicta ®), a 3-monthly ...

If approved, paliperidone palmitate 3-monthly injection will be the first once-every-three-months treatment for schizophrenia in the UK Janssen UK announced today that the Committee for Medicinal ...

Trial is the first to study schizophrenia treatment within the context of many real-world issues faced by patients with schizophrenia TITUSVILLE, N.J., April 15, 2015 /PRNewswire/ -- A study published ...

The US Food and Drug Administration (FDA) has approved a 6-month injection form of the long-acting atypical antipsychotic paliperidone palmitate (Invega Hafyera, Janssen Pharmaceuticals) for the ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA SUSTENNA contains the active ingredient paliperidone palmitate.

TITUSVILLE, N.J., Sept. 1, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical ...

The Food and Drug Administration has approved Invega Hafyera ™ (paliperidone palmitate), an every 6-month injection, for the treatment of schizophrenia in adults. Invega Hafyera is a long-acting ...

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional ...

UZEDY ® (1-month and 2-month subcutaneous risperidone for treatment of schizophrenia), is the first product based on Medincell's long-acting injection technology that reached commercial stage. UZEDY ...